London Covid case: Some rates rise as Britain falls

Recent case rates have been released to all local authorities in the UK and in most of them the infections are declining.

At the national level, 308 out of the 377 local areas in England (82 per cent) have experienced a decrease in cases and 65 (17 per cent) have experienced an increase.

Four are unchanged.

In south-east London, there are still some boroughs that are experiencing an increase in Covid cases.

These figures are accurate for the seven days to November 5 – with the last few days excluded for accuracy.

They are compared to a week before – the seven days until October 29.

The figures are based on the number of individuals who tested positive for Covid-19 in either a laboratory-reported or rapid lateral flow test, after the test date.

The rate is expressed as the number of new cases per 100,000 persons.


In Bexley, the Covid rate has fallen from 297.2 (741 cases) to 286.8 (715 cases).


In Bromley, the rate is 235.0 (782 cases) after falling from 293.9 (978 cases).


In Greenwich, the price has also fallen and is now at 204.5 (591 cases) from 231.5 (669 cases) the week before.


Lewisham is one of the only districts in south-east London that has seen an increase in cases – from 196.5 (600 cases) to 207.7 (634 cases).


The other is Southwark – where the case rate has increased from 174.1 (557 cases) to 183.1 (586 cases).


Nearby in Dartford, the case rate has dropped significantly from 508.5 (580 cases) to 406.0 (463 cases).

The list was compiled by the PA news agency using data released Nov. 9 on the government’s coronavirus dashboard.

It comes as the first anti-viral pill against Covid-19 that can be taken at home has been approved for use in the UK.

Molnupiravir is for people who have had a positive Covid test and have at least one risk factor for developing serious illness, such as obesity, being over 60, diabetes or heart disease.

The United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) said the drug is safe and effective in reducing the risk of hospitalization and death in people with mild to moderate Covid who are at extra risk for the virus.

The drug, from Ridgeback Biotherapeutics and Merck Sharp & Dohme (MSD), works by interfering with virus replication.

It prevents the virus from multiplying, keeps the level low in the body and therefore reduces the severity of the disease.

The MHRA said the drug should be taken as soon as possible after a positive Covid-19 test and within the first five days.

The government announced last month that it had secured 480,000 molnupiravir treatments after a study showed that it reduced the number of hospitalizations and deaths by 50% in mild to moderately ill patients who had at least one risk factor for the disease.

In the study, the tablet was given twice a day to patients recently diagnosed with coronavirus.

Health and Social Secretary Sajid Javid said: “Today is a historic day for our country as the UK is now the first country in the world to approve an antiviral drug that can be taken at home against Covid-19.

“This will be a game changer for the most vulnerable and the immunosuppressed, who will soon be able to receive the groundbreaking treatment.

“We are working at a pace across the government and with the NHS to set up plans to distribute molnupiravir to patients through a national study as soon as possible.

“This antiviral agent will be an excellent addition to our arsenal against Covid-19, and it remains important that everyone show up for their life-saving Covid-19 vaccine – especially those eligible for a booster – to ensure that as many people as possible are protected over the coming months. ”

Dr. June Raine, CEO of MHRA, said: “After a thorough review of data from our expert researchers and clinicians, we are satisfied that Lagevrio (molnupiravir) is safe and effective for those at risk of developing severe Covid- 19 disease and has given its approval.

“Lagevrio is another therapeutic agent to add to our arsenal against Covid-19.

It is also the world’s first approved antiviral agent for this disease that can be taken by mouth instead of being administered intravenously.

“This is important because it means it can be administered outside of a hospital setting before Covid-19 has progressed to a serious stage.

“Without compromising on quality, security and efficiency, the public can trust that the MHRA has performed a robust and thorough assessment of the data.”

Do you have a story for us? You can contact us here.

Follow us on Facebook, Twitter and Instagram to keep up with all the latest news.

Sign up for our newsletters to have updates sent directly to your inbox.

Leave a Comment